Table 1. Overview of patient clinical data.
| # | Sex | Age (years) | Race | pH | ABx | PPI | IMM | H. pyl.a | Other pt. clin. | End. indication | End. findings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 | F | 34 | AA | 7.5 | − | − | − | − | A, alcoholic hepatitis | UGIB | EG, MWT |
| 15 | F | 33 | AA | 7.0 | BL | + | G/M/CI | − | D, renal transplant | Melena, anemia | Erosive gastritis, RE |
| 16 | M | 45 | AA | 2.0 | − | − | − | + | G | Refractory hiccups | HH |
| 26 | F | 42 | AA | 6.0 | − | − | HIV/AIDS | + | G | Diarrhea, wt loss | CE, irreg. duodenal mucosa |
| 31 | M | 52 | C | 1.5 | − | + | − | − | G | Abdominal pain | HH |
| 33 | F | 71 | C | 1.0 | − | + | − | − | D, G, hyperparathyroidism | Dysphagia | GU |
| 34 | F | 72 | AA | 8.5 | − | + | G/M | 16S | G, renal transplant | Anemia | EG |
| 38 | M | 70 | C | 3.5 | − | + | − | − | A, D, G | BE | BE, EG |
| 41 | F | 38 | C | 4.5 | − | + | − | − | A, G | Screen for BE | GU, EG, no BE |
| 42 | M | 53 | AA | 7.0 | − | + | HIV/AIDS | glmM | HCV cirrhosis, T | Screen for EV | EG, no EV |
| 44 | M | 28 | AA | 1.0 | − | − | − | + | T | Abdominal pain | None |
| 48 | M | 36 | C | 3.0 | − | + | − | − | A, G | BE, diarrhea | BE |
| 49 | F | 33 | C | 1.0 | − | + | − | − | None | Abdominal pain | None |
| 50 | F | 79 | AA | 1.0 | − | − | − | − | D, G | BE | BE |
| 52 | F | 56 | AA | 6.5 | − | + | G | − | D, G, sarcoidosis | Nausea | EG |
| 56 | M | 68 | AA | 6.0 | − | + | − | − | G, CAD, CKD | Melena | HH, RE |
| 64 | M | 42 | AA | 7.0 | FQ | + | HIV/AIDS | − | G | Abdominal pain | EG |
| 67 | F | 67 | AA | 6.5 | − | + | G/M/CI | − | D, G, renal transplant | UGIB | EG |
| 68 | F | 50 | C | 1.5 | − | − | − | − | T | Abdominal pain | None |
| 76 | M | 42 | C | 2.5 | − | − | − | − | A, T | UGIB | GU, DU |
| 77 | M | 36 | C | 4.5 | − | − | − | − | None | Hematochezia | Duodenitis |
| 84 | M | 65 | C | 5.5 | ML | + | − | − | D, G | Screen for BE | EG, gastric polyps |
| 94 | M | 81 | AA | 6.5 | − | − | − | − | Pernicious anemia | Early satiety | Atrophic gastritis |
| 96 | F | 37 | AA | 5.5 | THF+ML | + | HIV/AIDS | − | G, gastroparesis, T | Diarrhea | Retained food |
| 97 | F | 27 | C | 1.0 | − | − | − | − | T | Abdominal pain | None |
Abbreviations: A, >1 alcoholic beverage per day; AA, African American; ABx, antibiotics (within 3 months before sampling) ; BE, Barrett's esophagus; BL, β-lactam+BL inhibitor; C, Caucasian; CAD, coronary artery disease; CE, candidal esophagitis; CI, calcineurin inhibitor; CKD, chronic kidney disease; D, diabetes; DU, duodenal ulcer(s); EG, erythematous gastropathy; End., endoscopic; EV, esophageal varices; F, female; FQ, fluoroquinolone; G, gastroesophageal reflux disease; G, glucocorticoids; GU, gastric ulcer(s) ; HH, hiatal hernia; IMM, immunosuppression; M, male; M, mycophenolate; ML, macrolide; MWT, Mallory–Weiss tear; PPI, proton pump inhibitor (at least 20 mg once daily for >1 day); pt. clin., patient clinical background; RE, reflux esophagitis; T, active tobacco use; THF, Tetrahydrofolate synthesis pathway-affecting antibiotic; UGIB, upper gastrointestinal bleeding; #, patient ID.
Identified by H. pylori glmM-specific PCR (glmM), by 16S rRNA gene amplicon sequencing (16S) or both (+).